Statewide coordinated STEMI approach deemed successful

Statewide coordinated STEMI approach deemed successful
A statewide coordinated effort across hospitals and emergency medical service providers to transport patients with ST-segment elevation myocardial infarction to hospitals providing percutaneous coronary intervention has resulted in improved outcomes, according to a study published online June 4 in Circulation.

(HealthDay) -- A statewide coordinated effort across hospitals and emergency medical service (EMS) providers to transport patients with ST-segment elevation myocardial infarction (STEMI) to hospitals providing percutaneous coronary intervention (PCI) has resulted in improved outcomes, according to a study published online June 4 in Circulation.

James G. Jollis, M.D., from Duke University in Durham, N.C., and colleagues analyzed performance data from the 119 North Carolina hospitals participating in a coordinated plan to treat STEMI patients according to presentation.

The researchers found that, between July 2008 and December 2009, 6,841 patients with STEMI were treated (median age, 59 years; 30 percent women). Of the treated patients, 3,907 presented directly to 21 PCI hospitals and 2,933 were transferred from a total of 98 non-PCI hospitals. Over the period analyzed, the rate of patients not receiving reperfusion decreased significantly from 5.4 to 4.0 percent. Treatment times improved substantially for patients requiring hospital transfer. For patients presenting directly to PCI hospitals, the median door-to-device times declined significantly, from 64 to 59 minutes, with EMS-transported patients the most likely to reach door-to-device treatment goals within 90 minutes (91 percent). Mortality was significantly lower for patients treated within guideline goals (2.2 percent, versus 5.7 percent for those exceeding ).

"By extending regional coordination to an entire state, rapid diagnosis and treatment of STEMI has become an established standard of care independent of health care setting or geographic location," the authors write.

Several authors disclosed to medical device and pharmaceutical companies, including Phillips, Sanofi-Aventis, and the Medtronic Foundation, all of which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Vitamin K antagonist plus clopidogrel feasible for PCI

5 hours ago

(HealthDay)—Vitamin K antagonists (VKA) combined with clopidogrel may be a better alternative to triple anticoagulant therapy in patients on long-term VKA undergoing percutaneous coronary intervention (PCI) ...

How pneumonia bacteria can compromise heart health

14 hours ago

Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality—but how the heart is ...

An autoimmune response may contribute to hypertension

Sep 17, 2014

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

User comments